Business
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc.
About this update from Allarity Therapeutics, Inc.
[{"type":"text","content":"- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that two patients enrolled in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy. The patients had been pre-screened using Allarity’s Drug Response Predictor (DRP®) companion diagnostic, which identified them as having a high likelihood of benefiting from stenoparib, the Company’s novel dual PARP/Tankyrase inhibitor. This remarkably lengthy treatment period highlights the potential of stenoparib to provide durable clinical benefit, even in heavily pre-treated ovarian cancer patients who have limited treatment options. The trial continues to evaluate stenoparib’s safety and efficacy, showing a confirmed, complete response as well as long term disease stability for multiple patients. Thomas Jensen, CEO of Allarity Therapeutics, commented on this clinical achievement: “We are incredibly encouraged by the sustained clinical benefit seen in these patients, who have now been on stenoparib for over a year. For heavily pre-treated ovarian cancer patients, extending life by 52 weeks is particularly noteworthy. Stenoparib’s unique mechanism of action, as both a PARP and Tankyrase inhibitor, sets it apart from other treatments. These results reinforce our belief in stenoparib’s potential as an important new therapy for ovarian cancer patients who have exhausted other treatment options.” Dr. Fernanda B. Musa, Director of Clinical Research in Gynecology Oncology and site Principal Investigator at the Swedish Cancer Institute for the trial added: “We have been surprised and excited to see a long duration of response to a single-agent oral therapy in patients with ovarian cancer who had failed multiple other types of treatment. I credit the success to personalized medicine: the pairing of the therapy to the patient’s specific tumor profile. I look forward to seeing further development of this program!” Allarity is actively planning the further advancement of its stenoparib program, with a focus on accelerating its path toward regulatory approval. The Company remains dedica...